Skip to main content

Table 1 Patient characteristics and previous chemotherapy

From: A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients

Characteristic

Number of patients (%)

Gender

 

   Male

16 (62)

   Female

10 (38)

Age (years)

 

   Mean (range)

58 (30-70)

ECOG Performance Status

 

   0

8 (31)

   1

18 (69)

Tumour Type

 

   Melanoma

8 (31)

   Colon, rectum or anus

3 (12)

   Non-small cell lung

3 (12)

   Sarcoma

3 (12)

   Glioblastoma

2 (8)

   Salivary gland

2 (8)

   Adrenal Cortex

1 (4)

   Cervix

1 (4)

   Head and neck

1 (4)

   Kidney

1 (4)

   Pancreas

1 (4)

Previous chemotherapy

 

   No. of courses

 

   None

4 (15)

   One

8 (31)

   Two

7 (27)

   Three

7 (27)